Relationships between electrocardiographic and echocardiographic findings in systemic sclerosis (scleroderma)

International Journal of Cardiology

Volumn 57, Issue 2, 1996, Pages 151-160

  Morelli, Sergio ^a   Sgreccia, Alessandro ^a   Ferrante, Luigi ^a   Barbieri, Claudio ^a   Bernardo, Maria L ^a   Perrone, Claudio ^a   De Marzio, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

echocardiography; electrocardiography; systemic sclerosis

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION; HEART DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PREVALENCE; PRIORITY JOURNAL; SYMPTOMATOLOGY; SYSTEMIC SCLEROSIS;

ADULT; AGED; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SCLERODERMA, SYSTEMIC; SENSITIVITY AND SPECIFICITY;

EID: 0030572976     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(96)02808-2     Document Type: Article

References (50)

1. [1] Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation 1976; 53: 483-490.
2. [2] Sackner MA, Akgun N, Kimbel P. Lewis DH. The pathophysiology of scleroderma involving the heart and respiratory system. Ann Intern Med 1964; 60: 611-630.
3. [3] Sackner MA, Heinz ER, Steinberg AJ. The heart in scleroderma. Am J Cardiol 1966; 17: 542-659.
4. [4] Siegel RS. Scleroderma. Med Clin North Am 1977; 61: 283-297.
5. [5] Medsger TA Jr, Masi AT. Survival with scleroderma II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chron Dis 1973; 26: 647-660.
6. [6] Wynn J, Fineberg N, Matzer L, et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985; 110: 123-127.
7. [7] Kazzam E, Caidahl K, Hällgren R, Gustafsson R, Waldenström A. Non-invasive evaluation of long-term cardiac effects of captopril in systemic sclerosis. J Intern Med 1991; 230: 203-212.
8. [8] Kahan A, Nitenberg A, Foult JM, et al. Decreased coronary reserve in primary scleroderma myocardial disease. Arthritis Rheum 1985; 28: 637-646.
9. [9] Kostis JB, Seibold JR, Turkevich D, et al. Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988; 84: 1007-1015.
10. [10] Roberts NK, Cabeen WR Jr, Moss J, Clements PJ, Furst DE. The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med 1981; 94: 38-40.
11. [11] Oram S, Stokes W. The heart in scleroderma. Br Heart J 1961; 23: 243-259.
12. [12] Escudero J, McDevitt E. The electrocardiogram in scleroderma. Analysis of 60 cases and review of the literature. Am Heart J 1958; 56: 846-855.
13. [13] Ridolfi RL, Bulkley BH, Hutchins GM. The cardiac conduction system in progressive system sclerosis: clinical and pathologic features of 35 patients. Am J Med 1976; 61: 361-366.
14. [14] James TN. Coronary arteries and conduction system in scleroderma heart disease. Circulation 1974; 50: 844-856.
15. [15] Gottdiener JS, Moutspoulos HM, Decker JL. Echocardiographic identification of cardiac abnormality in scleroderma and related disorders. Am J Med 1979; 66: 391-398.
16. [16] Clements PJ, Furst DE, Cabeen W, Tashkin D, Paulus HE, Roberts N. Relationship of arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis (PSS). Am J Med 1981; 71: 38-46.
17. [17] Weiss S, Stead EA, Warren JV, Bailey OT. Scleroderma heart disease with a consideration of certain other visceral manifestations of scleroderma. Arch Intern Med 1943; 71: 749-776.
18. [18] Follansbee WP, Curtiss EI, Ranhko PS, Medsger TA Jr, Lavine SJ, Owens GR, et al. The electrocardiogram in systemic sclerosis (scleroderma). Am J Med 1985; 79: 183-192.
19. [19] Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590.
20. [20] Le Roy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205.
21. [21] Fisch C. Electrocardiography and vectorcardiography. In: Braunwald E, editor. Heart disease: a textbook of cardiovascular medicine, 4th edn. Philadelphia, PA: W.B. Saunders Company, 1992; 116-160.
22. [22] Kaplan JD, Evans GT Jr, Foster E, Lim D, Schiller NB. Evaluation of electrocardiographic criteria for right atrial enlargement by quantitative two-dimensional echocardiography. J Am Coll Cardiol 1994; 23: 747-752.
23. [23] Romhilt DW, Estes EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J 1968; 75: 752-758.
24. [24] Murphy ML, Thenabadu PN, De Soyza N, et al. Reevaluation of electrocardiographic criteria for left, right and combined cardiac ventricular hypertrophy. Am J Cardiol 1984; 53: 1140-1147.
25. [25] Sahn DJ, DeMaria A, Kisslo J, Weyman A. The Committee on M-mode standardization of the American Society of Echocardiography, Recommendations regarding quantitation in M-mode echocardiographic measurements. Circulation 1978; 58: 1072-1082.
26. [26] Olson LJ, Tajik AJ. Echocardiographic evaluation of valvular heart disease. In: Marcus ML, Schelbert HR, Skorton DJ, Wolf GL, editors. Cardiac Imaging. Philadelphia, PA: Saunders, 1991; 419-448.
27. [27] Yock PG, Popp RL. Non-invasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657-662.
28. [28] Windesheim JH, Parkin TW. Electrocardiograms of ninety patients with acrosclerosis and progressive diffuse sclerosis (scleroderma). Circulation 1958; 17: 874-881.
29. [29] Leinwand I, Duryee AW, Richter MN. Scleroderma (based on a study of over 150 cases). Ann Intern Med 1954; 41: 1003-1041.
30. [30] Tuffanelli DL, Winkelmann RK. Systemic scleroderma: a clinical study of 727 cases. Arch Dermatol 1961; 84: 49-61.
31. [31] Montanes P, Lawless C, Black C, Oakley CM, Hughes G. The heart in scleroderma: noninvasive assessment. Clin Cardiol 1982; 5: 383-387.
32. [32] Duska F, Bradna P, Novak J, et al. Pyrophosphate heart scan in patients with progressive systemic sclerosis. Br Heart J 1982; 47: 90-93.
33. [33] Follansbee WP, Curtiss EI, Medsger TA Jr, Owens GR, Steen VD, Ronan GP. Myocardial function and perfusion in the CREST syndrome variant of progressive systemic sclerosis. Exercise radionuclide evaluation and comparison with diffuse scleroderma. Am J Med 1984; 77: 489-496.
34. [34] Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J 1985; 2: 399-411.
35. [35] Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation 1991; 84: 1136-1144.
36. [36] Surawicz B, Knoebel SB. Long QT: good, bad or indifferent? J Am Coll Cardiol 1984; 4: 398-413.
37. [37] Surawicz B. Electrophysiologic substrate of torsade de pointes: dispersion of repolarization or early afterdepolarizations? J Am Coll Cardiol 1989; 14: 172-184.
38. [38] Laakso M, Aberg A, Savola J, Pentikäinen PJ, Pyörälä K. Diseases and drugs causing prolongation of the QT interval. Am J Cardiol 1987; 59: 862-865.
39. [39] Sigurd B, Suenson M, Wennevold A, Sandoe E. Means of management of the long QT syndrome. In: Sandoe E, Julian DG, Bell JW, editors. Management of ventricular tachycardia - Role of mexiletine. Amsterdam: Excerpta Medica, 1978; 409-416.
40. [40] Abildskov JA. Adrenergic effects on the QT interval of the electrocardiogram. Am Heart J 1976; 92: 210-216.
41. [41] Yanowitz F, Preston JB, Abildskov JA. Functional distribution of right and left stellate innervation to the ventricles: production of neurogenic electrocardiographic changes by unilateral alteration of sympathetic tone. Circ Res 1966; 18: 416-428.
42. [42] Dessein PH, Joffe BI, Metz RM, Millar DL, Lawson M, Stanwix AE. Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Am J Med 1992; 93: 143-150.
43. [43] Klimiuk PS, Taylor L, Baker RD, Jason MIV Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 1988; 47: 542-545.
44. [44] Ewing DJ, Clarke BF. Autonomic neuropathy: its diagnosis and prognosis. Clin Endocrinol Metab 1986; 15: 855-888.
45. [45] Botstein GR, Le Roy EC. Primary heart disease in systemic sclerosis (scleroderma): advances in clinical and pathologic features, pathogenesis and new therapeutic approaches. Am Heart J 1981; 102: 913-919.
46. [46] D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46: 428-440.
47. [47] Bulkely BH, Klacsmann PG, Hutchins GM. Angina pectoris, myocardial infarction and sudden cardiac death with normal coronary arteries: a clinico-pathologic study of 9 patients with progressive systemic sclerosis. Am Heart J 1978; 95: 563-569.
48. [48] Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-524.
49. [49] Silver RM. Pulmonary hypertension secondary to systemic sclerosis (scleroderma). In: Weir EK, Archer SL, Reevs JT, editors. The diagnosis and treatment of pulmonary hypertension. Mount Kisko, NY: Futura, 1992; 191-207.
50. [50] Ungerer RG, Tashkin DP, Furst D, Clements PJ, Gong H Jr, Bein M, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75: 65-74.